IL202270A0 - Therapeutic pyrazoloquinoline derivatives - Google Patents

Therapeutic pyrazoloquinoline derivatives

Info

Publication number
IL202270A0
IL202270A0 IL202270A IL20227009A IL202270A0 IL 202270 A0 IL202270 A0 IL 202270A0 IL 202270 A IL202270 A IL 202270A IL 20227009 A IL20227009 A IL 20227009A IL 202270 A0 IL202270 A0 IL 202270A0
Authority
IL
Israel
Prior art keywords
formula
gabaa
animal
compound
pyrazoloquinoline derivatives
Prior art date
Application number
IL202270A
Other languages
English (en)
Original Assignee
Helicon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helicon Therapeutics Inc filed Critical Helicon Therapeutics Inc
Publication of IL202270A0 publication Critical patent/IL202270A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL202270A 2007-06-08 2009-11-22 Therapeutic pyrazoloquinoline derivatives IL202270A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94300507P 2007-06-08 2007-06-08
PCT/US2008/066201 WO2008154438A1 (en) 2007-06-08 2008-06-06 Therapeutic pyrazoloquinoline derivatives

Publications (1)

Publication Number Publication Date
IL202270A0 true IL202270A0 (en) 2010-06-16

Family

ID=40096440

Family Applications (1)

Application Number Title Priority Date Filing Date
IL202270A IL202270A0 (en) 2007-06-08 2009-11-22 Therapeutic pyrazoloquinoline derivatives

Country Status (13)

Country Link
US (2) US7872002B2 (enExample)
EP (1) EP2166852B1 (enExample)
JP (1) JP2010529143A (enExample)
KR (1) KR20100039331A (enExample)
CN (1) CN101742908A (enExample)
AT (1) ATE544344T1 (enExample)
AU (1) AU2008261884A1 (enExample)
BR (1) BRPI0812366A2 (enExample)
CA (1) CA2688395A1 (enExample)
ES (1) ES2386168T3 (enExample)
IL (1) IL202270A0 (enExample)
MX (1) MX2009013202A (enExample)
WO (1) WO2008154438A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2689934A1 (en) * 2007-06-08 2008-12-18 Helicon Therapeutics, Inc. Therapeutic pyrazolonaphthyridine derivatives
BRPI0812366A2 (pt) * 2007-06-08 2016-08-02 Helicon Therapeutics Inc composto, composição farmacêutica e métodos de modulação de um ou mais subtipos de gabaa, de tratamento de deficiência orgânica cognitiva e de desordem psiquiátrica e aumento de função cognitiva em animal e usos do composto ou da composição.
CA2688405A1 (en) * 2007-06-08 2008-12-18 Helicon Therapeutics, Inc. Therapeutic pyrazoloquinoline urea derivatives
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
WO2017085053A1 (en) 2015-11-16 2017-05-26 Fundación Para La Investigación Médica Aplicada Novel compounds as inhibitors of dna methyltransferases
CN105294648B (zh) * 2015-11-30 2017-11-28 山东罗欣药业集团股份有限公司 一种西他沙星的制备方法
WO2022037631A1 (zh) * 2020-08-21 2022-02-24 浙江海正药业股份有限公司 杂环类衍生物及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3204126A1 (de) * 1982-02-06 1983-08-11 Bayer Ag, 5090 Leverkusen Pyrazoloxazine, -thiazine, -chinoline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4814450A (en) 1984-07-09 1989-03-21 Ciba-Geigy Corporation Certain ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives
JPS61112075A (ja) * 1984-11-05 1986-05-30 Shionogi & Co Ltd チエニルピラゾロキノリン誘導体
EP0214092A1 (en) 1985-08-08 1987-03-11 Ciba-Geigy Ag Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
US5334595A (en) 1992-10-23 1994-08-02 Sterling Winthrop Inc. Pyrazoloquinolones as anticancer agents
GB9716347D0 (en) * 1997-08-01 1997-10-08 Merck Sharp & Dohme Therapeutic compounds
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
GB0108475D0 (en) * 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
JP3896309B2 (ja) 2001-07-09 2007-03-22 ファイザー株式会社 プロテインキナーゼｃ阻害物質としてのピラゾロキノリノン誘導体
ATE425164T1 (de) 2002-12-16 2009-03-15 Active Biotech Ab Tetrazyklische immunmodulierende verbindungen
TW200508233A (en) 2003-05-29 2005-03-01 Millennium Pharm Inc Chk-1 inhibitors
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
AU2006287378A1 (en) 2005-09-07 2007-03-15 Braincells, Inc. Modulation of neurogenesis by HDac inhibition
JP2008047893A (ja) * 2006-08-11 2008-02-28 Samsung Electronics Co Ltd 薄膜トランジスタ表示板及びその製造方法
BRPI0812366A2 (pt) * 2007-06-08 2016-08-02 Helicon Therapeutics Inc composto, composição farmacêutica e métodos de modulação de um ou mais subtipos de gabaa, de tratamento de deficiência orgânica cognitiva e de desordem psiquiátrica e aumento de função cognitiva em animal e usos do composto ou da composição.

Also Published As

Publication number Publication date
US7872002B2 (en) 2011-01-18
US20110065693A1 (en) 2011-03-17
ES2386168T3 (es) 2012-08-10
ATE544344T1 (de) 2012-02-15
US20080306049A1 (en) 2008-12-11
EP2166852B1 (en) 2012-02-08
HK1142775A1 (en) 2010-12-17
BRPI0812366A2 (pt) 2016-08-02
US8598159B2 (en) 2013-12-03
WO2008154438A1 (en) 2008-12-18
CN101742908A (zh) 2010-06-16
JP2010529143A (ja) 2010-08-26
KR20100039331A (ko) 2010-04-15
EP2166852A1 (en) 2010-03-31
MX2009013202A (es) 2010-04-09
AU2008261884A1 (en) 2008-12-18
EP2166852A4 (en) 2010-07-07
CA2688395A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
IL202270A0 (en) Therapeutic pyrazoloquinoline derivatives
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
MX2009013205A (es) Derivados de pirazoloquinolina urea terapeuticos.
UA86053C2 (ru) Соединения как модуляторы опиоидных рецепторов
TNSN07111A1 (en) Preparation and use of biphenyl-4-yl- carbonylamino acid derivatives for the treatment of obesity.
GEP20084360B (en) Substituted quinoline compounds
UA94639C2 (ru) Трициклические соединения и их применение как модуляторов глюкокортикоидного рецептора
EA201000100A1 (ru) Гетероциклические соединения, полезные в качестве ингибиторов mk2
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
EA200700262A1 (ru) Арилидены для лечения заболеваний, опосредуемых эстроген-родственным рецепторам альфа
MX2009013353A (es) Compuestos activadores de telomerasa y metodos para su uso.
MX2009011878A (es) Compuestos antagonistas de acido ribonucleico para la modulacion de beta-catenina.
MX2010003948A (es) N-fenil-birrolidin ureas sustituidas y uso terapeutico de las mismas.
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
EA201000362A1 (ru) Производные 1,3-дигидроизоиндола
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
MX2009013197A (es) Derivados terapeuticos de pirazolonaftiridina.
MXPA06000701A (es) Compuestos de sulfonildihidrobencimidazolona como ligandos de 5-hidroxitriptamina-6.
ATE466841T1 (de) 1-phenethylpiperidinderivate und ihre verwendung als opioidrezeptor-liganden
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
MX2009008286A (es) Compuestos triciclicos y su uso como moduladores del receptor de glucocorticosteroides.
NO20083045L (no) Benzimidazolderivater og deres anvendelse til modulering av GABAA-reseptorkomplekset
WO2007042544A3 (en) Imidazole derivatives and their use for modulating the gabaa receptor complex